Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lilly

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

Eli Lilly HQ

Lilly and AZ forge closer immuno-oncology bond

Look to boost their presence in a market predicted to be worth $30bn in 10 years

- PMLiVE

Lilly’s baricitinib beats Humira in trial for RA

Posts positive phase III data against the world's biggest-selling drug

- PMLiVE

Lilly drops evacetrapib on failed atherosclerosis trial

Leaves hole in company's late-stage pipeline

Eli Lilly HQ

Lilly acquires rights to intranasal glucagon spray

Could be first needle-less emergency treatment for hypoglycaemia

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

- PMLiVE

Axovant takes Alzheimer’s drug into phase III

Aims to bring first treatment in a decade to market

Eli Lilly HQ

Lilly set to launch Lantus biosimilar in the US next year

Settlement ends the company's legal dispute with Sanofi

- PMLiVE

Jardiance survival data wows diabetes conference

BoehringerIngelheim and Eli Lilly release top-line findings from landmark trial at EASD

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links